{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:31:15Z","timestamp":1777660275778,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HAB"],"published-print":{"date-parts":[[2018,5,7]]},"DOI":"10.3233\/hab-170330","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T12:14:35Z","timestamp":1507896875000},"page":"127-134","source":"Crossref","is-referenced-by-count":1,"title":["Neutralizing activity and safety of human monoclonal antibodies against hepatitis C virus"],"prefix":"10.1177","volume":"26","author":[{"given":"Camelia A.","family":"Abdel Malak","sequence":"first","affiliation":[{"name":"Department of Chemistry, Faculty of Science, Damietta University, Damietta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawfeek H.","family":"Abelhafez","sequence":"additional","affiliation":[{"name":"Department of Microbial Biotechnology, National Research Center, Giza, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf A.","family":"Tabll","sequence":"additional","affiliation":[{"name":"Department of Microbial Biotechnology, National Research Center, Giza, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad M.","family":"Mashaly","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science, Damietta University, Damietta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"El Shenawy","sequence":"additional","affiliation":[{"name":"Department of Microbial Biotechnology, National Research Center, Giza, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine S.","family":"El-Abd","sequence":"additional","affiliation":[{"name":"Department of Microbial Biotechnology, National Research Center, Giza, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maysa H.","family":"Shaker","sequence":"additional","affiliation":[{"name":"Animal Health Research Institute, Giza, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa K.","family":"El-Awady","sequence":"additional","affiliation":[{"name":"Department of Microbial Biotechnology, National Research Center, Giza, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"4902","key":"10.3233\/HAB-170330_ref1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"7","key":"10.3233\/HAB-170330_ref2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat Med"},{"issue":"13","key":"10.3233\/HAB-170330_ref3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.3233\/HAB-170330_ref4","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.3233\/HAB-170330_ref5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"issue":"9286","key":"10.3233\/HAB-170330_ref6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"13","key":"10.3233\/HAB-170330_ref7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.3233\/HAB-170330_ref8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.3233\/HAB-170330_ref9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/vim.2016.0123","article-title":"Mice Antibody Response to Conserved Nonadjuvanted Multiple Antigenic Peptides Derived from E1\/E2 Regions of Hepatitis C Virus","volume":"30","author":"Abdelhafez","year":"2017","journal-title":"Viral Immunol"},{"issue":"3-4","key":"10.3233\/HAB-170330_ref10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-140271","article-title":"Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1\/E2 protein of hepatitis C virus by EBV immortalization of immune CD22(+) B cells","volume":"22","author":"Tabll","year":"2013","journal-title":"Hum Antibodies"},{"issue":"4","key":"10.3233\/HAB-170330_ref11","first-page":"669","article-title":"Diagnosis of Hepatitis C Virus Infection Using a Novel Mouse Monoclonal Antibody to Detect Serum HCV E1\/E2 Antigens","volume":"63","author":"Touni","year":"2017","journal-title":"Clin Lab"},{"issue":"7","key":"10.3233\/HAB-170330_ref12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4254\/wjh.v9.i7.352","article-title":"Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C","volume":"9","author":"Ponziani","year":"2017","journal-title":"World J Hepatol"},{"issue":"3","key":"10.3233\/HAB-170330_ref13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1017\/S0025727300036632","article-title":"Monoclonal antibodies: a witness seminar in contemporary medical history","volume":"38","author":"Tansey","year":"1994","journal-title":"Med Hist"},{"issue":"5517","key":"10.3233\/HAB-170330_ref14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"5","key":"10.3233\/HAB-170330_ref15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.3233\/HAB-170330_ref16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-62703-586-6_6","article-title":"Production of human monoclonal antibodies by the epstein-barr virus method","volume":"1060","author":"Steinitz","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.3233\/HAB-170330_ref17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.0711044105","article-title":"Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization","volume":"22;105","author":"Scheel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/HAB-170330_ref18","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1016\/j.vaccine.2007.08.053","article-title":"Hepatitis C virus envelope glycoprotein immunization of rodents elicits crossreactive neutralizing antibodies","volume":"25","author":"Stamataki","year":"2007","journal-title":"Vaccine"},{"key":"10.3233\/HAB-170330_ref19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal Biochem"},{"key":"10.3233\/HAB-170330_ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-8981(99)00007-8","article-title":"Assay for hepatitis C virus in peripheral blood mononuclear cells enhances sensitivity of diagnosis and monitoring of HCVassociated hepatitis","volume":"283","author":"El-Awady","year":"1999","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.3233\/HAB-170330_ref21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2010.05.001","article-title":"A novel method for making human monoclonal antibodies","volume":"35","author":"Fraussen","year":"2010","journal-title":"J Autoimmun"},{"key":"10.3233\/HAB-170330_ref22","first-page":"7:28","article-title":"Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient","volume":"4","author":"Schieffelin","year":"2010","journal-title":"Virol J"},{"key":"10.3233\/HAB-170330_ref23","doi-asserted-by":"crossref","first-page":"i41","DOI":"10.1093\/ije\/dym285","article-title":"EBV Immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood","volume":"37","author":"Amoli","year":"2008","journal-title":"Int J Epidemiol"},{"key":"10.3233\/HAB-170330_ref24","first-page":"8:85","article-title":"Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells","volume":"12","author":"Funaro","year":"2008","journal-title":"BMC Biotechnol"},{"key":"10.3233\/HAB-170330_ref25","doi-asserted-by":"crossref","first-page":"450963","DOI":"10.1155\/2013\/450963","article-title":"Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies","volume":"2013","author":"Sautto","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"10","key":"10.3233\/HAB-170330_ref26","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J Virol"},{"issue":"14","key":"10.3233\/HAB-170330_ref27","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step","volume":"85","author":"Sabo","year":"2011","journal-title":"J Virol"}],"container-title":["Human Antibodies"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/HAB-170330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:02Z","timestamp":1777447322000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/HAB-170330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":27,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/hab-170330","relation":{},"ISSN":["1875-869X","1093-2607"],"issn-type":[{"value":"1875-869X","type":"electronic"},{"value":"1093-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,7]]}}}